Massimo Libra
Massimo Libra
Verified email at unict.it
TitleCited byYear
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance
JA McCubrey, LS Steelman, WH Chappell, SL Abrams, EWT Wong, ...
Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1773 (8), 1263-1284, 2007
19122007
Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance
JA McCubrey, LS Steelman, SL Abrams, JT Lee, F Chang, FE Bertrand, ...
Advances in enzyme regulation 46 (1), 249-279, 2006
6632006
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging
LS Steelman, WH Chappell, SL Abrams, CR Kempf, J Long, P Laidler, ...
Aging (Albany NY) 3 (3), 192, 2011
5102011
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health
WH Chappell, LS Steelman, JM Long, RC Kempf, SL Abrams, RA Franklin, ...
Oncotarget 2 (3), 135, 2011
4552011
Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia
LS Steelman, SL Abrams, J Whelan, FE Bertrand, DE Ludwig, J Bäsecke, ...
Leukemia 22 (4), 686, 2008
3492008
GSK-3 as potential target for therapeutic intervention in cancer
JA McCubrey, LS Steelman, FE Bertrand, NM Davis, M Sokolosky, ...
Oncotarget 5 (10), 2881, 2014
2942014
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance
JA McCubrey, LS Steelman, WH Chappell, SL Abrams, RA Franklin, ...
Oncotarget 3 (10), 1068, 2012
2542012
Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response
JA McCubrey, LS Steelman, WH Chappell, SL Abrams, G Montalto, ...
Oncotarget 3 (9), 954, 2012
2432012
Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy
JA McCubrey, LS Steelman, SL Abrams, FE Bertrand, DE Ludwig, ...
Leukemia 22 (4), 708, 2008
2292008
Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy
LS Steelman, RA Franklin, SL Abrams, W Chappell, CR Kempf, J Bäsecke, ...
Leukemia 25 (7), 1080, 2011
2102011
Targeting the leukemic stem cell: the Holy Grail of leukemia therapy
N Misaghian, G Ligresti, LS Steelman, FE Bertrand, J Bäsecke, M Libra, ...
Leukemia 23 (1), 25, 2009
2082009
Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention
NM Davis, M Sokolosky, K Stadelman, SL Abrams, M Libra, S Candido, ...
Oncotarget 5 (13), 4603, 2014
1842014
Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway
AM Martelli, C Evangelisti, W Chappell, SL Abrams, J Bäsecke, F Stivala, ...
Leukemia 25 (7), 1064, 2011
1632011
Multifaceted roles of GSK-3 and Wnt/β-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention
JA McCubrey, LS Steelman, FE Bertrand, NM Davis, SL Abrams, ...
Leukemia 28 (1), 15, 2014
1492014
PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches
G Ligresti, L Militello, LS Steelman, A Cavallaro, F Basile, F Nicoletti, ...
Cell cycle 8 (9), 1352-1358, 2009
1492009
The tumor microenvironment in hepatocellular carcinoma
GC Leonardi, S Candido, M Cervello, D Nicolosi, F Raiti, S Travali, ...
International journal of oncology 40 (6), 1733-1747, 2012
1482012
Melanoma: molecular pathogenesis and emerging target therapies
AE Russo, E Torrisi, Y Bevelacqua, R Perrotta, M Libra, JA McCubrey, ...
International journal of oncology 34 (6), 1481-1489, 2009
1472009
Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways
JA McCubrey, LS Steelman, CR Kempf, WH Chappell, SL Abrams, ...
Journal of cellular physiology 226 (11), 2762-2781, 2011
1452011
Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use
GM Nitulescu, D Margina, P Juzenas, Q Peng, OT Olaru, E Saloustros, ...
International journal of oncology 48 (3), 869-885, 2016
1422016
Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors
LS Steelman, PM Navolanic, ML Sokolosky, JR Taylor, BD Lehmann, ...
Oncogene 27 (29), 4086, 2008
1422008
The system can't perform the operation now. Try again later.
Articles 1–20